Corticosteroids & Sepsis Recovery: New Study Findings

Moderate-Dose Corticosteroids Substantially Improve Sepsis Recovery Rates, New Research Confirms

A new study published in the Journal of Intensive Medicine provides compelling evidence that moderate-dose corticosteroid treatments can substantially reduce symptoms and accelerate recovery for patients battling sepsis, a life-threatening condition affecting millions globally.

Did you know? – Sepsis, a severe reaction to infection, affects about 50 million people worldwide each year. It occurs when the body’s response to an infection damages its own tissues and organs. Early treatment, including corticosteroids, is crucial for improving patient outcomes.

Sepsis arises when the body’s immune response to an infection spirals out of control, causing widespread organ damage. Globally, the condition represents a massive public health burden, with an estimated 50 million cases and over 11 million deaths annually. While containing the spread of infection and rapid treatment are crucial, the only consistently effective treatment for sepsis once it develops has been the use of corticosteroids to modulate the immune response.

Pro tip: – corticosteroids help stabilize mitochondria in immune cells, reducing inflammation. They also limit the release of molecules that cause cell death, lessening stress on vital organs. This dual action is key to the drugs’ effectiveness in treating sepsis.

Researchers from France,led by Professor Djillali Annane of the IHU SEPSIS Thorough Sepsis Center,meticulously examined the mechanisms by which corticosteroids mitigate sepsis-related damage. Their comprehensive review of nearly 100 research articles revealed that corticosteroids stabilize mitochondria within dysfunctional immune cells, shifting their activity from promoting inflammation to reducing it. Furthermore, the drugs limit the release of molecules that trigger unregulated cell death, known as necrosis, thereby lessening stress on vital organs.

“Although international guidelines have helped reduce crude mortality rates from sepsis, there are still no specific therapies other than corticosteroids,” explained Professor Annane. “Our objectives were to provide the most recent data on corticosteroids, as well as up-to-date evidence regarding their effects in patients with sepsis.”

Reader question: – What are the potential downsides of corticosteroid treatment for sepsis? Share your thoughts on the balance between benefits and risks.

The research also highlighted the protective effects of corticosteroids on the cardiovascular system, preventing dangerous blood vessel dilation and restoring responsiveness to norepinephrine – both critical for maintaining healthy blood pressure during sepsis.Multiple studies cited by the team demonstrate that higher doses of corticosteroids correlate with a reduced risk of cardiovascular and organ failure, suppressed inflammation, and shorter hospital stays.

Though, the benefits are not without potential risks. Researchers found a moderate to high certainty of increased blood glucose and sodium levels in patients treated with corticosteroids.Additionally, the use of these drugs during the COVID-19 pandemic appeared to be linked to a higher risk of opportunistic infections.

Professor Annane emphasized the need for further research to identify which patients will derive the greatest benefit from corticosteroid treatment while minimizing potential adverse effects. To aid clinicians, the team developed a decision tree based on their analysis:

• For sepsis resulting from COVID-19 or other viral respiratory infections, treatment with dexamethasone is recommended.
• In cases of bacterial pneumonia-induced sepsis, hydrocortisone should be initiated, with the addition of fludrocortisone if the patient develops septic shock.

Treatment specifics will always depend on individual patient history and the progression of their illness.

Ultimately, Professor Annane concluded that “the use of moderate doses of corticosteroids for a week or two in patients with sepsis is supported by biological and pharmacological rationale, evidence from clinical trials, and high-quality systematic reviews and meta-analyses, as well as clinical practice guidelines.”

more information: Jihene Mahmoud et al, corticostero